TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.
Researchers identified a vulnerable pathway in hard-to-treat leukemia cells, suggesting a potential new drug target.
TRIM24 stabilizes the AML oncogenic transcription factor CUX1 (p110 isoform) through the deubiquitinase USP10, protecting it from proteasomal degradation and promoting chemoresistance. The TRIM24-USP10-CUX1 axis represents a potentially druggable vulnerability in chemoresistant AML.
What the study was
- Study design
- mechanistic_preclinical
- Category
- hematologic_malignancies
- Maturity
- Exploratory
Why it surfaced
Identifies a novel druggable molecular axis underlying AML chemoresistance—a critical clinical problem where new therapeutic strategies are urgently needed. Open-access J Transl Med study with mechanistic depth. Relevant to hematologic malignancies watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.